Professor
Stanford University
Stanford, CA, United States
Dr. Chris Holsinger is Professor and Chief of Head and Neck Surgical Oncology at Stanford University.
Dr. Holsinger received his medical degree from Vanderbilt School of Medicine in 1995, completed his internship and residency at Baylor College of Medicine and his Fellowship in head and neck surgical oncology at The University of Texas M. D. Anderson Cancer Center. In 2003, he was awarded Fulbright Scholarship to study surgery at the University of Paris with Professor Ollivier Laccourreye and with Professor Wolfgang Steiner at the Georg-August University in Göttingen.
From 2003-2013, Dr. Holsinger worked at the Department of Head and Neck Surgery at the University of Texas M.D. Anderson Cancer Center. In 2013, Dr. Holsinger moved to Stanford University, where at the Cancer Center led H&N Multidisciplinary Cancer Care Clinical Program for the next 5 years. At Stanford he has held a variety of leadership positions including Director of Robotics and Division Chief of Head and Neck Surgery. As Chief of H&N Surgical Oncology, he works to unify efforts in the Department of Otolaryngology to streamline and unify cancer care by defining principles and practice of surgical oncology.
Dr Holsinger's research focuses on surgical innovation and clinical trials. He currently serves Co-Chair of the Surgical Subcommittee, for the NRG Oncology’s Head and Neck Working Group. He serves as surgical principal investigator for RTOG920 and coordinated surgeon-credentialing for ECOG 3311, a prospective clinical trial to study robotic head and neck surgery. He led the largest multicenter review of transoral robotic surgery in 2015 and recently completed a multicenter FDA investigative device exemption trial to evaluate the safety and efficacy of a next-generation single-port robotic surgical system.
Evidenced-Based Approach to Oropharynx Cancer, 2024
Saturday, September 28, 2024
9:30 AM – 10:30 AM EDT
Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.